Presentation is loading. Please wait.

Presentation is loading. Please wait.

Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation  Vijaya.

Published byThoralf Birkeland Modified over 5 years ago

Similar presentations

Presentation on theme: "Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation  Vijaya."— Presentation transcript:

1 Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation  Vijaya Raj Bhatt, Fausto R. Loberiza, Kim Schmit-Pokorny, Stephanie J. Lee  Biology of Blood and Marrow Transplantation  Volume 22, Issue 6, Pages (June 2016) DOI: /j.bbmt Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 Schema for subject selection in payer process for hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 Time from initiation of payer approval to actual approval by payer type. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

4 Figure 3 Time from approval to transplantation by payer type.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

5 Figure 4 Overall survival of the entire cohort based on 3 indices of timeliness of insurance approval and transplantation. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

6 Figure 5 Overall survival of the lymphoma patients based on 3 indices of timeliness of insurance approval and transplantation. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

7 Figure 6 Overall survival of the myeloma patients based on 3 indices of timeliness of insurance approval and transplantation. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

8 Figure 7 Overall survival of the leukemia patients based on 3 indices of timeliness of insurance approval and transplantation. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2016 The American Society for Blood and Marrow Transplantation Terms and Conditions

Download ppt "Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation  Vijaya."

Similar presentations

A Simplified Procedure for Hematopoietic Stem Cell Amplification Using a Serum-Free, Feeder Cell-Free Culture System Ian M. Rogers, Nobuko Yamanaka, Robert.

A Simplified Procedure for Hematopoietic Stem Cell Amplification Using a Serum-Free, Feeder Cell-Free Culture System Ian M. Rogers, Nobuko Yamanaka, Robert.
Steven Joffe, Michelle M. Mello, E. Francis Cook, Stephanie J. Lee 

Steven Joffe, Michelle M. Mello, E. Francis Cook, Stephanie J. Lee 
Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation  Patricia M. Sheean,

Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation  Patricia M. Sheean,
Michael A. Pulsipher, Christina Peters, Ching-Hon Pui 

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui 
Mohamed A. Kharfan-Dabaja, Claudio Anasetti, Edgardo S. Santos 

Mohamed A. Kharfan-Dabaja, Claudio Anasetti, Edgardo S. Santos 
In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,
How to Treat MDS without Stem Cell Transplantation

How to Treat MDS without Stem Cell Transplantation
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
Steven Joffe, Michelle M. Mello, E. Francis Cook, Stephanie J. Lee 

Steven Joffe, Michelle M. Mello, E. Francis Cook, Stephanie J. Lee 
Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma  Taewoong Choi, Murali K. Kodali, Wen-Kai Weng 

Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma  Taewoong Choi, Murali K. Kodali, Wen-Kai Weng 
Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non- Hodgkin Lymphoma: Effect of Histological Grade and Follicular International.

Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non- Hodgkin Lymphoma: Effect of Histological Grade and Follicular International.
Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes 

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes 
Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic.

Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic.
Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors  Kenneth.

Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors  Kenneth.
Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous.

Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous.
Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation  Patricia M. Sheean,

Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation  Patricia M. Sheean,
Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,
Sabina Kersting, Leo F. Verdonck 

Sabina Kersting, Leo F. Verdonck 
Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.
Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection and Cases of Recurrent and Late Infection.

Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection and Cases of Recurrent and Late Infection.

Similar presentations

Ads by Google